Table 2.
Primary outcome.
| Outcome/analysis | No. (%) |
||
|---|---|---|---|
| Bamlanivimab (n = 128) |
Bamlanivimab -etesevimab (n = 885) |
Casirivimab -imdevimab (n = 922) |
|
| Primary outcome, hospital-free days, median (IQR) | 28 (28–28) | 28 (28–28) | 28 (28–28) |
| Patients with 28 hospital-free days | 112 (87.5) | 755 (85.3) | 790 (85.7) |
| Subcomponents of hospital-free days | |||
| Deaths | 1 (0.8) | 7 (0.8) | 6 (0.7) |
| Hospital length of stay among hospitalized patients, median days (IQR) |
4 (2−10) | 4 (3–7) | 3 (2–6) |
| Hospitalized | 16 (12.5) | 130 (14.7) | 132 (14.3) |
| After mAb infusion in ED | 8/25 (32.0) | 100/422 (23.7) | 100/460 (21.7) |
| After mAb infusion in IC | 8/103 (7.8) | 30/463 (6.5) | 32/462 (6.9) |
| Primary analysis of the primary outcome | |||
| Adjusted odds ratio | |||
| mean (SD) | 0.62 (0.22) | 0.95 (0.13) | 1 [reference] |
| median (95% credible interval) | 0.58 (0.30–1.16) | 0.94 (0.72–1.24) | 1 [reference] |
| Probability of inferiority to bamlanivimab-etesevimab, % | 91% | .. | 34% |
| Probability of inferiority to casirivimab-imdevimab, % | 94% | 66% | .. |
| Probability of equivalence between bamlanivimab-etesevimab and casirivimab-imdevimab, prespecified bounds, % | |||
| 0.25 | .. | 86% | |
| 0.20 | .. | 77% | |
| 0.15 | .. | 64% | |
| 0.10 | .. | 47% | |
| 0.05 | .. | 25% | |
Abbreviations: IQR, interquartile range; mAb, monoclonal antibodies; ED, emergency department; IC, infusion center; SD, standard deviation.